Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective analysis of progression-free (PFS) and overall survival (OS) in the “Real Life” by M. A., Fabbri et al.
Session F. Genitourinary cancer
F23 Abiraterone acetate inmetastatic castration-resistant prostate
cancer after chemotherapy. A retrospective analysis of
progression-free (PFS) and overall survival (OS) in the “Real Life”
M.A. Fabbri1, M.A. Fabbri1, D. Santini2, E. Cortesi3, T. Gamucci4, P. Marchetti5,
F. Longo6, F. Angelini7, I. Sperduti8, A. Milano5, A. Pellegrino9, F. Nelli1, F. Primi1,
R. Raffaele10, M.L. Mancini11, S. Quadrini4, A. Giuli6, E.M. Ruggeri1
1UOC Oncologia, Ospedale Belcolle, viterbo
2Oncologia Medica, Campus Biomedico, Roma
3Oncologia Medica B, Policlinico Umberto I, Roma
4Oncologia Medica, Ospedale SS. Trinità, Sora
5UOC Oncologia, Ospedale Sant’ Andrea, Roma
6UOC Oncologia A, Policlinico Umberto I, Roma
7UOC Oncologia, Ospedale Regina Apostolorum, Albano Laziale
8Dipartimento di Statistica, IRE, Roma
9UOC Oncologia, Ospedale FBF, Roma
10UOC Oncologia, Campus Biomedico, Roma
11UOC Oncologia B, Policlinico Umberto I, Roma
Background: Abiraterone acetate (AA) is a potent, selective androgen (CYP17)
biosynthesis inhibitor, which showed to improve overall survival (HR = 0.646) in
mCRPC patients progressing after docetaxel. In this retrospective analysis we
assessed the PFS and OS safety in patients affected with mCRPC progressing
after chemotherapy, treated in the normal clinical practice, in several Italian
Oncologic Units.
Material and methods:We retrospectively reviewed the clinical data of patients
affected with mCRCP progressive after chemotherapy who received AA (1000 mg/d)
plus prednisone (5 mg/twice daily). Pts were considered eligible if they had received
docetaxel as prior chemotherapy. A total of 189 patients were included in the analysis.
Main patient characteristics were: median age: 70 years (range 44-89), Gleason score
>7: 84%; median PSA at AA start: 35 (range 0.36–2100); duration of prior hormonal
therapy <12 vs ≥ 12 months: 38 vs 62%; no. of metastatic sites: 1 vs≥ 2: 73 vs 27%;
bone only 48%, presence of visceral disease 51%; symptomatic vs non-symptomatic: 53
vs 47%; median number of prior docetaxel courses: 6 (range 1-20); second-line
cabazitaxel: 14%. Forty-four percent of patients received bisphosphonates during AA
treatment.
Results: At a median follow-up of 8.5 months (range 1-51) the median
progression-free survival (PFS) and the median overall survival (OS) were 10 months
(95% CI: 7-13) and 26 months (95% CI: 17-35) respectively. No differences in PFS and
OS were found based on the response to docetaxel. Patients who received hormonal
treatment for≥ 12 months had a statistically significant longer PFS (13 vs 7 months,
p = 0.009) and OS (28 vs 17 months, p = 0.03 months). The median decrease in the
PSA level > 50% was observed in 36% of patients. Patients with only bone metastasis
had a PFS of 13 (95% CI: 7.18) and OS 28 months (95% CI:16-40). Twelve patients
(6%) presented a scheletal-related event (SRE). AAwas well tolerated and no relevant
toxicity were observed.
Conclusions: The PFS and the OS achieved in this analysis although retrospective,
confirms the activity and safety of AA in these subset of patients.
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